Program in respiratory diseases found a first target, and inflammatory pain project now has two compounds.

Pharmacopeia identified two new lead compounds in its alliance with GlaxoSmithKline. Pharmacopeia will hence receive a $1 million milestone fee.

The first molecule will reportedly form the basis of a lead optimization program related to respiratory disease. The other candidate is the second from the inflammatory pain project. The identification of the first molecule in the alliance related to inflammatory pain triggered a $500,000 milestone payment.

Pharmacopeia reports that it has received $10 million from GSK in connection with early discovery activities and is entitled to $5 million more upon the completion of further early discovery work. Pharmacopeia is also entitled to success-based milestone payments totaling up to $83 million per program and potentially double-digit royalties on the sales of any product.

Previous articleAPP to Implement Thermo Fisher Scientific’s Darwin LIMS
Next articleFovea and Genzyme Ally to Research Retinal Dystrophies